Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TGF-beta upregulated long non-coding RNA in lung cancer (TBULC)
- Target
- TBULC
- Molecular classification
- Long non-coding RNA (lncRNA)
01
Overview
TGF-beta upregulated long non-coding RNA in lung cancer (TBULC, also known as CTD-2033D15.2 or TGF-beta upregulated lncRNA in lung cancer) is a nuclear-localized, non-coding RNA of 1,020 nucleotides located on chromosome 15. Induced by TGF-beta stimulation via the Smad2/3 pathway, TBULC expression is markedly upregulated in non-small cell lung cancer (NSCLC) tissues, where it promotes tumor invasion, migration, and metastasis, likely through facilitating epithelial-mesenchymal transition (EMT) and other oncogenic processes. High expression of TBULC has been validated as a poor prognostic marker and an independent prognostic factor in NSCLC cohorts[1][2]. As of recent studies, TBULC is under investigation as a potential diagnostic, prognostic, and possibly therapeutic target, although there are no clinically approved drugs specifically targeting this lncRNA. TBULC is distinct from THBS1-AS1 and should not be confused with antisense or intronic THBS1 transcripts.
- Other names
- TBULCTGF-beta upregulated lncRNA in lung cancerCTD-2033D15.2
02
Biological functions
Promotes cell invasionPromotes cell migrationFacilitates epithelial-mesenchymal transition (EMT)Oncogenic function in NSCLC
03
Disease associations
Cancer (especially non-small cell lung cancer)
04
Safety considerations
Therapeutic targeting challenges common to lncRNAs: specificity, delivery, off-target effectsNo established safety concerns in clinical use since no clinical inhibitors exist yet
05
Biomarkers
Prognostic biomarker for non-small cell lung cancer (high expression predicts poor outcome)
Beyond the preview
Go deeper on TGF-beta upregulated long non-coding RNA in lung cancer (TBULC).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TGF-beta upregulated long non-coding RNA in lung cancer (TBULC).